CLINICAL_TRIALS
trial_result
· 2014-04-11
Clinical Trial Update: Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis [Phase 2]
Summary
This is a Phase 2 trial update of intravenous immune globulin (IGIV) for relapsing-remitting multiple sclerosis, with results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Grifols Therapeutics LLC | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED | Results posted: 2014-04-11